Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418907 | 0.93 | SMN1; SMN2 (0.32) | PDE7ALTA4HSMN1; SMN2 | |
| SCHEMBL3387753 | 0.93 | SMN1; SMN2 (0.32) | PDE7ALTA4HSMN1; SMN2 | |
| SCHEMBL13377825 | 0.79 | ALDH1A1 (0.35) | PDE7ALTA4H | |
| SCHEMBL13377829 | 0.77 | PDE7A (0.32) | PDE7ALTA4H | |
| SCHEMBL13377821 | 0.76 | LTA4H (0.37) | PDE7ALTA4HSMN1; SMN2 | |
| SCHEMBL718126 | 0.74 | LTA4H (0.34) | PDE7ALTA4H | |
| SCHEMBL13377822 | 0.74 | PDE7A (0.35) | PDE7ALTA4H | |
| SCHEMBL21222568 | 0.74 | LTA4H (0.34) | PDE7ALTA4H | |
| SCHEMBL13722593 | 0.74 | LTA4H (0.34) | PDE7ALTA4H | |
| SCHEMBL26881047 | 0.73 | LTA4H (0.32) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766884-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | PDE7A 4184/4885LTA4H 4341/4885SMN1; SMN2 4086/4885 |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | PDE7A 4184/4885LTA4H 4341/4885SMN1; SMN2 4086/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | PDE7A 3397/4885LTA4H 3677/4885SMN1; SMN2 2884/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | PDE7A 3343/4885LTA4H 3677/4885SMN1; SMN2 2951/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | PDE7A 3343/4885LTA4H 3677/4885SMN1; SMN2 2951/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | PDE7A 3343/4885LTA4H 3677/4885SMN1; SMN2 2951/4885 |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | PDE7A 4184/4885LTA4H 4341/4885SMN1; SMN2 4086/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | PDE7A 3343/4885LTA4H 3677/4885SMN1; SMN2 2951/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | PDE7A 3343/4885LTA4H 3677/4885SMN1; SMN2 2951/4885 |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | PDE7A 4184/4885LTA4H 4341/4885SMN1; SMN2 4086/4885 |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | PDE7A 4184/4885LTA4H 4341/4885SMN1; SMN2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.